vTv Therapeutics Inc. 8K

vTv Therapeutics reported Q2 2026 results, outlined sufficient cash runway through the anticipated Phase 3 cadisegliatin topline readout, and detailed upcoming clinical and investor events for its type 1 diabetes program.

On August 6, 2026, vTv Therapeutics Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting a cash balance of $86.6 million and a net loss of $13.1 million for the quarter, and provided a corporate update stating that enrollment in its Phase 3 CATT1 trial of cadisegliatin for type 1 diabetes is expected to complete in the third quarter of 2026, that a Phase 2a Hybrid CATT1 trial in hybrid closed-loop insulin users is expected to initiate before year end 2026, and that the company believes its current cash resources will fund operations through the anticipated CATT1 topline data readout while it also plans a key opinion leader event in the fourth quarter of 2026.

Filing Facts

CIK

1641489

Ticker

-

Form

8K

Source Type

sec

Accession

0001641489-26-000029

Alert Tier

6